| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
44,215,000 |
| Market
Cap: |
3.69(M) |
| Last
Volume: |
900 |
Avg
Vol: |
59,812 |
| 52
Week Range: |
$0.06 - $0.22 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Enzon Pharmaceuticals is engaged in existing licensing arrangements with other companies primarily related to sales of certain drug products that utilize Co.'s proprietary technology. Co. has a marketing agreement relating to the drug Vicineum.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
99,550 |
99,550 |
| Total Buy Value |
$0 |
$0 |
$13,910 |
$13,910 |
| Total People Bought |
0 |
0 |
1 |
1 |
| Total Buy Transactions |
0 |
0 |
2 |
2 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Rackear Andrew D |
VP and General Counsel |
• – – |
2013-01-23 |
4 |
A |
$0.00 |
$0 |
D/D |
4,686 |
78,019 |
|
- |
|
| Conover Charles |
SVP, R&D Program Management |
• – – |
2013-01-23 |
4 |
A |
$0.00 |
$0 |
D/D |
2,343 |
74,793 |
|
- |
|
| Icahn Carl C Et Al |
10% Owner |
– – • |
2012-11-28 |
4 |
D |
$0.00 |
$0 |
I/I |
(694,023) |
5,904,863 |
|
- |
|
| Icahn Carl C Et Al |
10% Owner |
– – • |
2012-11-28 |
4 |
OE |
$0.00 |
$0 |
I/I |
694,023 |
6,598,886 |
|
- |
|
| Hebard George |
Interim PEO and Interim COO |
• • – |
2012-11-07 |
4 |
A |
$0.00 |
$0 |
D/D |
24,500 |
43,237 |
|
- |
|
| Lebuhn Robert |
Director |
– • – |
2012-08-14 |
4 |
S |
$6.58 |
$38,308 |
D/D |
(5,820) |
98,115 |
|
- |
|
| Lebuhn Robert |
Director |
– • – |
2012-08-10 |
4 |
S |
$6.58 |
$12,720 |
D/D |
(1,933) |
103,935 |
|
- |
|
| Mulligan Richard |
Director |
– • – |
2012-07-02 |
4 |
A |
$0.00 |
$0 |
D/D |
18,670 |
49,064 |
|
- |
|
| Denner Alexander J |
Director |
– • – |
2012-07-02 |
4 |
A |
$0.00 |
$0 |
D/D |
21,338 |
60,620 |
|
- |
|
| Young Richard A |
Director |
– • – |
2012-07-02 |
4 |
A |
$0.00 |
$0 |
D/D |
10,669 |
30,231 |
|
- |
|
| Salisbury Robert C |
Director |
– • – |
2012-07-02 |
4 |
A |
$0.00 |
$0 |
D/D |
10,669 |
67,707 |
|
- |
|
| Lebuhn Robert |
Director |
– • – |
2012-07-02 |
4 |
A |
$0.00 |
$0 |
D/D |
10,669 |
105,868 |
|
- |
|
| Deuel Thomas |
Director |
– • – |
2012-07-02 |
4 |
A |
$0.00 |
$0 |
D/D |
10,669 |
32,231 |
|
- |
|
| Hebard George |
Interim PEO and Interim COO |
• • – |
2012-06-20 |
4 |
B |
$6.88 |
$34,395 |
D/D |
5,000 |
18,737 |
2.81 |
- |
|
| Rackear Andrew D |
VP and General Counsel |
• – – |
2012-06-05 |
4 |
S |
$6.81 |
$10,983 |
D/D |
(1,614) |
56,720 |
|
- |
|
| Conover Charles |
SVP, R&D Program Management |
• – – |
2012-06-05 |
4 |
S |
$6.78 |
$169,500 |
D/D |
(25,000) |
57,213 |
|
- |
|
| Daly Timothy |
VP, Controller and PAO |
• – – |
2012-03-28 |
4 |
A |
$0.00 |
$0 |
D/D |
8,000 |
8,000 |
|
- |
|
| Young Richard A |
Director |
– • – |
2012-03-15 |
4 |
S |
$6.92 |
$13,842 |
D/D |
(2,000) |
19,562 |
|
- |
|
| Hebard George |
Director |
– • – |
2012-02-27 |
4 |
A |
$0.00 |
$0 |
D/D |
13,737 |
13,737 |
|
- |
|
| Conover Charles |
SVP, R&D Program Management |
• – – |
2012-01-17 |
4 |
A |
$0.00 |
$0 |
D/D |
10,000 |
82,213 |
|
- |
|
| Greenberger Lee M |
VP, Research |
• – – |
2012-01-17 |
4 |
A |
$0.00 |
$0 |
D/D |
3,500 |
36,146 |
|
- |
|
| Buchbinder Aby |
VP, Clinical Development |
• – – |
2012-01-17 |
4 |
A |
$0.00 |
$0 |
D/D |
4,000 |
58,015 |
|
- |
|
| Rackear Andrew D |
VP and General Counsel |
• – – |
2012-01-17 |
4 |
A |
$0.00 |
$0 |
D/D |
10,000 |
58,334 |
|
- |
|
| Stancic Ana |
Executive VP, COO, PEO, CFO |
• – – |
2012-01-17 |
4 |
A |
$0.00 |
$0 |
D/D |
45,000 |
70,000 |
|
- |
|
| Stancic Ana |
Executive VP, COO, PEO, CFO |
• – – |
2012-01-17 |
4 |
D |
$0.00 |
$0 |
D/D |
(45,000) |
15,000 |
|
- |
|
394 Records found
|
|
Page 4 of 16 |
|
|
